FDA Attempts To Carve Out Regulatory Policy For Cytogenetic Tests
This article was originally published in The Pink Sheet Daily
Executive Summary
Array-based cytogenetic tests detect DNA copy number changes that may be indicative of congenital anomalies or developmental disabilities, but rather than a specific biomarker they can survey all or part of the entire genome and the results are open to interpretation.